CSPI Comment to CMS re: National Coverage Analysis (NCA) Proposed Decision Memo on Aducamab

CSPI shares the belief of many scientists and researchers that the FDA's approval of aducanumab was not based on adequate scientific evidence of the drug’s effectiveness. In this comment, we encourage the Centers for Medicare and Medicaid Services not to approve aducamab outside of clinical trials.